Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$0.31.

  • Cyclerion Therapeutics' EPS (Basic) changed N/A to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.31, marking a year-over-year increase of 7375.23%. This contributed to the annual value of $3.14 for FY2023, which is 12637.31% up from last year.
  • Per Cyclerion Therapeutics' latest filing, its EPS (Basic) stood at -$0.31 for Q3 2025.
  • In the past 5 years, Cyclerion Therapeutics' EPS (Basic) ranged from a high of $5.53 in Q3 2023 and a low of -$6.16 during Q2 2022
  • For the 5-year period, Cyclerion Therapeutics' EPS (Basic) averaged around -$0.88, with its median value being -$0.55 (2024).
  • In the last 5 years, Cyclerion Therapeutics' EPS (Basic) plummeted by 126888.89% in 2022 and then skyrocketed by 29756.55% in 2023.
  • Cyclerion Therapeutics' EPS (Basic) (Quarter) stood at -$0.24 in 2021, then crashed by 454.72% to -$1.33 in 2022, then surged by 515.63% to $5.53 in 2023, then plummeted by 109.96% to -$0.55 in 2024, then skyrocketed by 43.43% to -$0.31 in 2025.
  • Its EPS (Basic) was -$0.31 in Q3 2025, compared to -$0.54 in Q2 2025 and -$0.57 in Q1 2025.